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Polyunsaturated Fatty Acids (PUFA)s
Overview of n-3 PUFAs
Polyunsaturated fatty acids have two or more double bonds within the hydrocarbon chain. Omega-3 polyunsaturated
fatty acids (n-3 PUFAs) have the first double bond 3 carbons away from the end of the chain. Commonly mentioned n-3
PUFAs include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are found in fish, flax seed,
canola oil, and pharmaceutical preparations (Sakamoto, et al, 2019). n-3 PUFAs have gained attention due to observed
anti-inflammatory effects. These anti-inflammatory effects are important as inflammation is the primary cause of
cardiovascular diseases (Willerson and Ridker, 2004). However, epidemiological research in humans has generated
mixed results which may be due in part to the particular n-3 PUFA under study, as drug trials have provided clear
evidence that EPA has benefits for those at risk of cardiovascular diseases (Bhatt et al., 2019).
Mechanisms of Inflammation Resolution
The mechanisms by which n-3 PUFAs reduce inflammation are proposed to involve their conversion to other
compounds. The enzymatic metabolism of EPA and DHA results in the production of lipid mediators known as
specialized proresolving mediators (SPM), which promote inflammation resolution. SPMs include resolvins, marsins,
and protectins (Bäck, 2017). D-series resolvins and protectins result from DHA, while E-series resolvins come from
EPA. These molecules act on G-protein-coupled receptors (GPCR) to activate an inflammation resolution response. In
the case of atherosclerosis, these molecules reduce the risk of immunosuppression that causes unresolved inflammation
in this disease (Carracedo et al., 2019). n-3 PUFAs can also modulate membrane fluidity so that dimerization and
recruitment of toll-like receptor-4 (TLR-4) is disrupted, which reduces the activity of nuclear factor-kappaB (NF-𝜅B),
and thus reduces inflammation (Mozaffarian and Wu, 2011). Baker et al. (2018) found that EPA and DHA reduce
expression of vascular cell adhesion molecule 1, resulting in a subsequent decrease in adhesion of leukocytes, as well as
leukocyte infiltration, to the vasculature. EPA and DHA can regulate inflammatory gene expression in order to modulate
cytokine, chemokine, and adhesion molecule activity to reduce inflammation as well (Darwesh et al., 2019). Liu et al.
(2016) evaluated the effect of DHA on inflammation through activation of free fatty acid receptor 4 (FFA4). This study
examined human endothelial cell line EA.hy926 treated with 100µM DHA for 16 hours, followed by 1ng/mL TNF-ɑ.
TNF-ɑ induces Egr-1 gene expression, as well as increases the interaction between TAK1 and TAB2 in order to induce
inflammation. DHA reduces these effects, suggesting that DHA can resolve inflammation through its effect on TNF-ɑ
signaling pathway through the FFA4. Therefore, DHA-induced activation of FFA4 reduces inflammation (Liu et al.,
2016).
Clinical Studies on Inflammation Resolution through n-3 PUFAs
Makarewicz-Wujec et al. (2017) in a double-blind trial with 30 participants following a myocardial infarction (MI)
found that n-3 PUFA supplementation did not experience significant reductions in inflammatory markers. Participants
supplemented 1g/day n-3 PUFAs (fish oil with DHA and EPA) for 12 weeks. No significant difference was observed
between placebo and treatment groups in regards to inflammatory markers such as C reactive peptide (CRP), monocyte
chemoattractant protein - 1 (MCP-1), homocysteine, or CD-40 (Makarewicz-Wujec et al., 2017). Hu et al. (2017) in an
analysis of randomized controlled trials involving 487 patients found that n-3 PUFA supplementation did not reduce
inflammatory markers. The authors report serum levels of CRP (SMD, -0.20; 95% CI, -0.44 to 0.05; p=0.11), IL-6
(SMD, 0.00; 95% CI, -0.33 to 0.33; p=0.99) and TNF-α (SMD, 0.14; 95 % CI, -0.17 to 0.44; p=0.38) between the
omega-3 fatty acids supplementation group and control (Hu et al., 2017). The compiled studies supplemented 0.86g/day n-3 PUFAs, for 2-6 months. The ASCEND Study Collaborative Group (2018) examined the effect of 840 mg
EPA and DHA supplementation per day for 7 years in type 2 diabetics to find that n-3 PUFAs do not reduce end point
major cardiovascular events (3% difference between placebo and treatment groups). Major cardiovascular events were
defined as fatal MI, nonfatal stroke, transient ischemic attacks, and fatal cardiovascular events. This study did find a
19% reduction in fatal cardiovascular events. (ASCEND Study Collaborative Group, 2018). Manson et al. (2019) in the
VITAL study found similar results with 840 mg EPA and DHA per day with 2,000 IU vitamin D3 in healthy participants
for 5 years. The VITAL study found a non-significant 8% decrease in major end point cardiovascular events from the
treatment to the placebo group. Major end point cardiovascular events were defined as stroke, fatal cardiovascular
disease, and myocardial infarction. However this study did report a 28% decrease in MI incidence with the treatment
group (Manson et al., 2019), (Kris-Etherton et al., 2019).
Contrary to the above studies, Bhatt et al. (2019) in the REDUCE-IT trial, with 3,600mg EPA supplementation by
icosapent ethyl supplement (IPE) per day for 5 years in participants already on a statin, reported a 26% decrease in
primary cardiovascular disease end point events. Primary cardiovascular disease end points were defined as fatal
cardiovascular events, fatal and nonfatal MI, unstable angina, fatal and nonfatal stroke, and urgent revascularization,
among other cardiovascular diseases (Bhatt et al., 2019), (Kris-Etherton et al., 2019). IPE is approved by the FDA under
the trade name Vascepa. Budoff et al. (2019) examined similar effects at 9 months with Vascepa in the EVAPORATE
study, reporting a 20% decrease in the primary end point in the treatment group with interim results, compared to the
control. EVAPORATE includes 80 participants with coronary atherosclerosis and elevated triglycerides prescribed a
statin. The primary endpoint is defined as a change in low-attenuation plaque volume (Budoff et al., 2018; Budoff et al.,
2019).
Summary
Notably, between null and significant studies examining the clinical significance of n-3 PUFA supplementation, the dose
and duration of n-3 PUFA has been variable. Further, the specific n-3 PUFA under study has been variable. In order to
better assert the clinical significance of the anti-inflammatory mechanisms of n-3 PUFAs, studies should better analyze
the importance of supplementation duration, as well as clarify the minimum effective dose for clinical significance.
Further, research examining the importance of the specific n-3 PUFA under study will provide insight into the degree of
significance in the relationship between n-3 PUFA supplementation and anti-inflammatory effects.

Atherosclerosis
Atherogenesis:
Atherogenesis (the development of atherosclerotic plaques) is a complex process involving several factors all of
which are driven by a chronic inflammatory response. Atherosclerosis is a multifocal disease that attacks sites with low
or oscillatory shear stresses on the endothelium. These sites of low/oscillating shear occur where the laminar flow of
blood is disturbed by a curvature or vessel branch. These inflamed regions develop due to the activation of the NF-Kß
pathway in endothelial cells (Denis et al, 2017). NF-kß is an important inflammatory signaling molecule (Halade et al,
2018). Once activated, NF-kß travels to the nucleus to increase expression of the protein of inflammation. This increase
in NF-kß signaling in the endothelium, along with the presence of oxidized LDL (oxLDL) particles circulating in the
blood, causes the expression of adhesion proteins in the endothelium (VCAM, ICAM, selectin, etc) that recruit
leukocytes to these regions (Baker et al, 2018). Once the monocyte are held by the endothelium in these inflamed
regions, they migrate across the endothelium and enter the intima. Once on the other side of the endothelium, the
monocytes transition to activate macrophages. They remain in this location (the vascular intima) and begin to absorb
the oxLDL particles (Baker et al, 2018). These oxLDL particles enter the vessel intima due to the increase endothelial
cell permeability. As macrophages are unable to degrade the oxLDL, the macrophages continue to absorb oxLDL until
they turn into foam cells (oxLDL laden macrophages). Two phenotypes of macrophage (M1 and M2) have been
identified in atherosclerotic plaques that both secreting cytokines. The M1 macrophage cytokines are more
proinflammatory than M2 (Bentzon et al, 2014; Conti, 2015). The M1 macrophages release the cytokine tumor necrosis
factor (TNF) which stimulated the apoptosis of foam cells (Conti, 2015). The death of these foam cells causes the
formation of a necrotic core in the plaque as it enlarges (Bentzon et al, 2014). The intimal enlargement of the plaque
derives from the cytokines released by the macrophages that thicken the intimal layer by enhancing endothelial
permeability to allow more LDL and monocyte to enter the intimal layer (Baker et al, 2018). Smooth muscle cells
migrate to the intima where are converted to a synthetic phenotype that secretes growth factors (eg., platelet derived
growth factor) that stimulate more smooth muscle cell to migrate. In addition to the growth factors, they also secrete
collagen that forms the basis for the plaque: the enlargement in the intimal layer (Bentzon et al, 2014).
Inflammatory cytokines
Inflammation is tightly connected to atherogenesis. During atherogenesis, macrophages releases cytokines that
further the inflammatory response (Conti, 2015). M1 cells release many cytokines including IL-1 and TNF. IL-1
induces TNF which stimulates apoptosis in endothelial cells as well as reducing growth factor secretion. These growth
factors are also considered cytokines. M2 cells also release important cytokines like IL-10. IL-10 can deactivates M1
macrophages which contributes to the progression of the plaque (Conti, 2015). TNF from M1 cells upregulates
expression of ICAM’s and VCAM’s which recruits more monocytes.
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Abstract
Consumption of omega-3 fatty acids benefits the
cardiovascular system by reducing blood vessel inflammatory
responses. Our recent work showed omega-3 fatty acids
decrease connexin 43 (Cx43) expression in cultured
endothelial cells after 1 day. Our interest was Cx43as a
marker of inflammation as omega-3 fatty acids are strongly
implicated as anti-inflammatory agents.
Localized
inflammatory responses drive the growth of the
atherosclerotic plaques responsible for a majority of
cardiovascular diseases. Anything that affects the
inflammatory response will affect the growth (and stability
which is also important) of those plaques. This poster will
summarize current knowledge of atherosclerosis and
inflammation as well as the impact of omega-3 fatty acids on
inflammation.

Summary
The original poster was to have presented evidence on the

impact of plating density on culture endothelial cell
expression of Cx43. This was based upon controls
experiments in the lab that showed a decrease in Cx43
with increasing cell density The ultimate goal of this
research was to better understand how inflammation
affects endothelial cells (with Cx43 as a marker of
inflammation in the endothelium) and more importantly
the protective effects of PUFAs (omega-3 in particular)
on inflammatory response (the original work showed
omega-3 fatty acids decreased Cx43 expression at 24 and
48 hours of treatment). The student authors had collected
proteins and were waiting to run the Western blots when
the covid-19 hit. Thus, Madison (first column) and Kyle
(second column) on short notice, wrote this quick review
of PUFAs and atherogenesis.
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